[go: up one dir, main page]

DK0751766T3 - Nasal og okular indgivelse af ketamin til behandling af smerter og til afgiftning - Google Patents

Nasal og okular indgivelse af ketamin til behandling af smerter og til afgiftning

Info

Publication number
DK0751766T3
DK0751766T3 DK95913499T DK95913499T DK0751766T3 DK 0751766 T3 DK0751766 T3 DK 0751766T3 DK 95913499 T DK95913499 T DK 95913499T DK 95913499 T DK95913499 T DK 95913499T DK 0751766 T3 DK0751766 T3 DK 0751766T3
Authority
DK
Denmark
Prior art keywords
pain
ketamine
nasal
detoxification
treatment
Prior art date
Application number
DK95913499T
Other languages
Danish (da)
English (en)
Inventor
Stuart L Weg
Original Assignee
Stuart L Weg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stuart L Weg filed Critical Stuart L Weg
Application granted granted Critical
Publication of DK0751766T3 publication Critical patent/DK0751766T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK95913499T 1994-02-25 1995-02-24 Nasal og okular indgivelse af ketamin til behandling af smerter og til afgiftning DK0751766T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/201,756 US5543434A (en) 1994-02-25 1994-02-25 Nasal administration of ketamine to manage pain
PCT/US1995/002418 WO1995022965A2 (fr) 1994-02-25 1995-02-24 Administration nasale et oculaire de ketamine pour le traitement de la douleur et les desintoxications

Publications (1)

Publication Number Publication Date
DK0751766T3 true DK0751766T3 (da) 2002-02-11

Family

ID=22747152

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95913499T DK0751766T3 (da) 1994-02-25 1995-02-24 Nasal og okular indgivelse af ketamin til behandling af smerter og til afgiftning

Country Status (11)

Country Link
US (1) US5543434A (fr)
EP (1) EP0751766B1 (fr)
JP (1) JP4729148B2 (fr)
AT (1) ATE206913T1 (fr)
CA (1) CA2184077C (fr)
DE (1) DE69523295T2 (fr)
DK (1) DK0751766T3 (fr)
ES (1) ES2165910T3 (fr)
MX (1) MX9603633A (fr)
PT (1) PT751766E (fr)
WO (1) WO1995022965A2 (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
EP0814790B1 (fr) * 1995-02-24 2003-07-16 Stuart L. Weg Administration de ketamine pour assurer une desintoxication
US5496537A (en) * 1995-03-23 1996-03-05 Henry; Richard A. Propofol hydrofluorocarbon propellant formulations
JPH11511466A (ja) * 1995-08-30 1999-10-05 スチュアート エル ウェグ 苦痛を管理しおよび薬物依存性を軽減するための、ケタミンの投与
US6197830B1 (en) * 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US20040034107A1 (en) * 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
EP1103256A1 (fr) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Utilisation de la kétamine pour le traitement de la dysfonction immunitaire neuroendocrine et du psyhosyndrome algogénique
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
WO2002011778A1 (fr) * 2000-05-10 2002-02-14 University Of Kentucky Research Foundation Systeme et procede d'administration intranasale d'opioides
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
EP2255806A3 (fr) 2000-07-31 2011-06-29 Nycomed Danmark ApS Compositions de fentanyl pour utilisation nasale
US6948492B2 (en) * 2000-08-15 2005-09-27 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US20030138508A1 (en) * 2001-12-18 2003-07-24 Novack Gary D. Method for administering an analgesic
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
EP1392262A1 (fr) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Administration d'esters medicamenteux par inhalation
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
CA2447519C (fr) * 2001-05-24 2008-09-16 Alexza Molecular Delivery Corporation Administration par voie pulmonaire d'alprazolam, d'estazolam, de midazolam ou de triazolam
EP1404331B1 (fr) * 2001-07-06 2007-10-31 Penwest Pharmaceuticals Co. Formulations d'oxymorphone a liberation lente
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
AU2002318211B2 (en) 2001-07-06 2007-07-12 Endo Pharmaceuticals, Inc. Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
AU2002337686B2 (en) * 2001-09-26 2008-05-15 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
WO2003041693A1 (fr) * 2001-11-09 2003-05-22 Alexza Molecular Delivery Corporation Administration de diazepam a travers une voie pulmonaire
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
NZ540282A (en) * 2002-11-18 2008-06-30 Yaupon Therapeutics Inc Analgesic uses of norketamine and ketamine/norketamine prodrugs
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20040213828A1 (en) * 2003-04-23 2004-10-28 Smith David J. Pain relief lollipop compositions and methods
EP1625335A2 (fr) 2003-05-21 2006-02-15 Alexza Pharmaceuticals, Inc. Unite de chauffage autonome a allumage optique ou electrique, et unite d'administration de medicament utilisant cette unite de chauffage
CA2542837A1 (fr) * 2003-10-21 2005-05-12 Arakis Ltd. Utilisation de substances non opiacees pour potentialiser les opiaces
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP1781360A1 (fr) 2004-08-12 2007-05-09 Alexza Pharmaceuticals, Inc. Dispositif de distribution de drogue par aérosol intégrant des conditionnements thermiques actionnés par percussion
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
WO2007111880A2 (fr) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Administration intra-nasale de ketamine pour traiter la depression
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
WO2009103150A1 (fr) * 2008-02-20 2009-08-27 Kevin David Smith Procédé de traitement des migraines
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
BR112015003796A2 (pt) * 2012-08-23 2017-07-04 L Weg Stuart composição ansiolítica, formulação e método de uso
CN105073096A (zh) 2013-03-15 2015-11-18 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
JP6462663B2 (ja) 2013-04-12 2019-01-30 アイカーン スクール オブ メディシン アット マウント シナイ 心的外傷後ストレス障害を処置するための方法
SI3043785T1 (sl) 2013-09-13 2022-02-28 National University Corporation Chiba University Uporaba R-ketamina in njegove soli kot farmacevtska sredstva
CN106714789A (zh) 2014-08-13 2017-05-24 詹森药业有限公司 用于治疗抑郁症的方法
CA2961208A1 (fr) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Regimes posologiques specifiques au genotype val66met (snp rs6265) et methodes pour le traitement de la depression
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US10555952B2 (en) 2015-06-19 2020-02-11 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10391102B2 (en) 2015-06-19 2019-08-27 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10166240B2 (en) 2015-06-19 2019-01-01 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10179136B2 (en) 2015-06-19 2019-01-15 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
EP4413979A3 (fr) * 2015-06-19 2024-11-20 Melt Pharmaceuticals, Inc. Compositions pharmaceutiques pour des applications anesthésiologiques
US20200297734A1 (en) 2015-06-19 2020-09-24 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
CN117531017A (zh) 2017-12-22 2024-02-09 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮
WO2019152873A1 (fr) 2018-02-02 2019-08-08 Alexza Pharmaceuticals, Inc. Dispositif aérosol à condensation électrique
BR112020016500A2 (pt) 2018-02-15 2020-12-15 National University Corporation Chiba University Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea
CN118121577A (zh) 2018-05-04 2024-06-04 感知神经科学公司 治疗物质滥用的方法
US11154537B2 (en) 2018-08-10 2021-10-26 Eleusis Therapeutics Us, Inc. Method of treatment for ketamine infusion
EP3934632A4 (fr) 2019-03-05 2022-11-23 Janssen Pharmaceuticals, Inc. Eskétamine pour le traitement de la dépression
DK3976012T3 (da) 2019-05-31 2024-04-15 Afyx Dev A/S Intranasal administration af ketamin til patienter med klyngehovedpine
US11160799B2 (en) * 2019-10-22 2021-11-02 Cessatech A/S Pediatric combination
TW202139981A (zh) 2020-01-22 2021-11-01 美商西羅斯醫療公司 降低nmda拮抗劑之副作用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4334526A (en) * 1979-05-24 1982-06-15 Hamacher Edward N Method for administering a dissociative, unconscious type of anesthesia
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US5132114A (en) * 1985-05-01 1992-07-21 University Of Utah Research Foundation Compositions and methods of manufacture of compressed powder medicaments
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration

Also Published As

Publication number Publication date
DE69523295T2 (de) 2002-07-11
ATE206913T1 (de) 2001-11-15
MX9603633A (es) 1998-01-31
CA2184077A1 (fr) 1995-08-31
DE69523295D1 (de) 2001-11-22
CA2184077C (fr) 2007-12-11
JP4729148B2 (ja) 2011-07-20
ES2165910T3 (es) 2002-04-01
WO1995022965A2 (fr) 1995-08-31
EP0751766B1 (fr) 2001-10-17
PT751766E (pt) 2002-04-29
WO1995022965A3 (fr) 1995-12-21
JPH10500664A (ja) 1998-01-20
EP0751766A1 (fr) 1997-01-08
US5543434A (en) 1996-08-06

Similar Documents

Publication Publication Date Title
DK0751766T3 (da) Nasal og okular indgivelse af ketamin til behandling af smerter og til afgiftning
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
DK1014966T3 (da) Farmaceutisk præparat til behandling af neurologiske og neuropsykiatriske lidelser
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
DK19893A (da) Praeparat til nasal behandling
DK0723444T3 (da) Levobupivacain, som er egnet til behandling af kronisk smerte
DK64592D0 (da) Peptider til terapeutisk behandling
NO972391L (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
SE9304098L (sv) Anordning för fallskyddad klättring
DK0846173T3 (da) Anvendelse af et anti-interleukin-9-antistof til fremstilling af et lægemiddel til behandling af astma
DK0637242T3 (da) Midler til behandling af stofmisbrugslidelser
FI973023L (fi) Liikakasvusairauksien yhdistetty terapeuttinen hoito
PT888330E (pt) Metodos de tratamento ou prevencao de cistite intersticial
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
NO982463D0 (no) Anvendelse av en kombinasjon av pentoksyfyllin og type I-interferoner til behandling av multippel sklerose
DE69924979D1 (de) Behandlung von chronischen schmerzen
NO990450L (no) Behandling av sinnslidelser
IT1288399B1 (it) Medicamento per il trattamento terapeutico della maculopatia legata all'eta', della maculopatia non legata all'eta' e per la profilassi
DK0869785T3 (da) 4-Hydroxycoumarin-3-carboxyamider til behandling af ikke-insulinafhængig diabetes mellitus
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
FI950696A0 (fi) Menetelmä HIV:n replikaation estämiseksi IL-4:ää käyttämällä
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
NO962503L (no) Anvendelse av penoksyfyllin ved behandling av multippel sklerose
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
NO984198D0 (no) Fremgangsmåte for behandling av aggresjon